Barely Significant
← all excerpts

Outcomes with frontline immune checkpoint inhibitors among individuals with <i>BRAF</i>-mutant non-small cell lung cancer.

Front Oncol · 2025 · PMC12727587 · PMID 41450930

Europe PMCDOI
2
hedged sentences
0.0700
closest p · 1.4× alpha
0.0700
boldest claim

The sentences

showed a trendp = 0.07so close (0.05 < p ≤ 0.1)
In patients with non-Class I mutations, tobacco users treated with ICI-based therapies (n=36) showed a trend towards improved PFS (14.2 vs. 7.5 months; p = 0.07) and OS (18.8 vs. 9.7 months; p = 0.07) compared to never-smokers (n=6).

also in 53,322 other papers

did not reach statistical significanceno p-value reported
These differences, however, did not reach statistical significance likely due to the limited cohort size.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.